The latest addition to ResearchAndMarkets.com’s offerings is the ‘Global Monkeypox Diagnostics Market by Assay, Country, Product, and Place, featuring Executive & Consultant Guides, along with Market Analysis & Forecasts for the years 2022-2026’ report.
The report forecasts the Monkeypox Diagnostics Market size up to 2026, reflecting the urgent declaration of Monkeypox as a health emergency. Recent data indicates a rapid spread of the outbreak beyond African regions, prompting governments worldwide to gear up for widespread testing to curb the threat early on. This creates significant opportunities for the In Vitro Diagnostic industry.
While growth stems from fundamental factors, the COVID-19 pandemic has reshaped the market landscape, influencing it both now and in the foreseeable future. While some players have established themselves, disruptive diagnostic technologies could potentially alter the competitive dynamics. This report delves into the market, exploring emerging trends such as Rapid Diagnostics and the Genomics Revolution, which converge to create new diagnostic avenues.
The scope of the report covers an extensive overview of the global Monkeypox Diagnostics Market, including:
- Monkeypox Diagnostics Market Overview by Country
- Monkeypox Diagnostics Market Overview by Assay
- Monkeypox Diagnostics Market Overview by Product
- Monkeypox Diagnostics Market Overview by Place
Furthermore, the report delves into specific categories within the Monkeypox Diagnostic Market:
- Assay Types (PCR, NGS, Rapid, Other Assays, Biomarker Other)
- Product Categories (Instrumentation, Consumables, Software & Service)
- Place Segments (Hospital, Clinic/POL, Other Places)
Key topics covered in the report include market guides, situation analysis, and guides tailored for executives, marketing staff, investment analysts, and management consultants. Additionally, it provides an introduction and market definition, shedding light on the current science behind Monkeypox, industry overview, market trends, recent developments, and profiles of key companies in the sector.
Some notable recent developments highlighted in the report include:
- The U.S. declaration of Monkeypox as a public health emergency
- BioGX receiving CE-IVD Mark for Multigene POC Test
- The World Health Organization declaring Monkeypox a global emergency
- Quest offering internally developed Monkeypox Test
- FDA 510(k) clearances for CDC, Abbott, Roche, and BioMerieux
- Increased Monkeypox testing by commercial and academic labs
- Collaboration between Becton Dickinson and CerTest Biotec on Monkeypox MDx
- Ongoing sequencing efforts to understand the virus better
The report also profiles key companies driving innovation and advancements in Monkeypox diagnostics, including Abbott Diagnostics, Bio-Rad Laboratories, Quest Diagnostics, Roche Molecular Diagnostics, and Thermo Fisher Scientific Inc., among others.
